CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 276 enrolled
Drug / intervention
Probiotic +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02803827
NCT02803827Phase 3Completed

Optimizing the Management of Pediatric Acute Diarrhoeal Disease in Botswana

Hamilton Health Sciences Corporation·interventional·Posted Jun 17, 2016·Updated Feb 26, 2019

In Brief

A Phase 3 clinical trial evaluating Rapid diagnostics, Probiotic, and 1 other intervention for Acute Gastroenteritis. Completed, enrolled 276 participants across 4 sites.

Detailed Summary

Many children admitted to hospital in Botswana without bloody diarrhoea are presumed to have viral gastroenteritis and so not treated with antibiotics - but they may indeed have a treatable cause for their illness. The investigators will conduct a randomized trial to see if rapid testing using novel methods to identify potentially treatable causes of diarrhoea leads to improved outcomes. The investigators will also be randomizing children to Lactobacillus reuteri DSM (daughter strain) 17938 therapy versus placebo (the standard of care) to see if this treatment decreases the duration of diarrhoea. The proposed study is a large multi-centre trial following the previous pilot trial.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBotswana

Timeline

Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedJun 17, 2016
Enrollment StartJun 1, 2016
Primary CompletionJan 1, 2019
Study CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 10.0 years ago

Interventions

Rapid diagnosticsother

Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.

Probioticbiological

The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.

Placeboother

The placebo will be the vegetable oil vehicle and look identical to the probiotic.